[Infectious complications of biologic therapy in patients with rheumatoid arthritis].
The introduction of biological disease-modifying drugs (DMARDs) has substantially improved the treatment options for patients with rheumatoid arthritis. However, infectious complications represent the most common side effects of these drugs, including severe infections as well as rare opportunistic infections. Treating patients on biological DMARDs is therefore one of the biggest challenges in rheumatology care. The present review describes the current state of knowledge regarding frequency and type of infectious complications associated with biological DMARDs. The article focuses mainly on risk management, in particular on diagnosis and recurrence prevention of tuberculosis and reactivation of hepatitis B virus infection. Furthermore, we discuss the importance of vaccinations in primary disease prevention in patients with rheumatoid arthritis.
Klinik für Immunologie und Rheumatologie, Medizinische Hochschule Hannover, Carl-Neuberg-Strasse 1, Hannover, Germany. meyer.dirk@mh-hannover.de
D
D
Meyer-Olson
K
K
Hoeper
R E
RE
Schmidt
D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology; D001688:Biological Products / Q000009:adverse effects* / Q000627:therapeutic use; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000097:blood; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D009894:Opportunistic Infections / Q000139:chemically induced* / Q000276:immunology; D012306:Risk; D012307:Risk Factors; D013601:T-Lymphocytes / Q000276:immunology
D018501:Antirheumatic Agents; D001688:Biological Products; D016207:Cytokines; D007166:Immunosuppressive Agents